[Low-dose danazol therapy in idiopathic thrombocytopenic purpura].
Danazol was administered orally at a dosage of 50 mg/day to 17 patients (11 females and 6 males) with idiopathic thrombocytopenic purpura refractory to steroids and/or splenectomy. The patients had not been treated with conventional dosages of danazol. The drug was suspended in four patients because of adverse effects of danazol. In 13 patients (8 females and 5 males, mean age 44 y. o.) who received the danazol therapy for more than 6 months, there were no patients with an excellent response, and one patient had a good response to the therapy. The rest of the patients did not respond to danazol.
Nozaki
H
H
Fourth Department of Internal Medicine, Tokai University School of Medicine.
Tanaka
K
K
Yonekura
S
S
Shimizu
M
M
Komatsuda
M
M
Nagao
T
T
Arimori
S
S
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D003613:Danazol / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011696:Purpura, Thrombocytopenic / Q000188:drug therapy*
D003613:Danazol